Harvest Fund Management Co. Ltd Boosts Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

by · The Cerbat Gem

Harvest Fund Management Co. Ltd lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 43.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,791 shares of the company’s stock after buying an additional 1,153 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in IDEXX Laboratories were worth $1,915,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Davis R M Inc. raised its holdings in IDEXX Laboratories by 0.8% in the third quarter. Davis R M Inc. now owns 103,378 shares of the company’s stock worth $52,229,000 after purchasing an additional 793 shares in the last quarter. Daiwa Securities Group Inc. grew its position in shares of IDEXX Laboratories by 10.1% in the 3rd quarter. Daiwa Securities Group Inc. now owns 16,462 shares of the company’s stock worth $8,316,000 after buying an additional 1,510 shares during the period. Summit Trail Advisors LLC increased its stake in shares of IDEXX Laboratories by 11.5% in the 3rd quarter. Summit Trail Advisors LLC now owns 784 shares of the company’s stock worth $396,000 after acquiring an additional 81 shares in the last quarter. Centaurus Financial Inc. purchased a new position in IDEXX Laboratories during the 3rd quarter valued at about $115,000. Finally, Larson Financial Group LLC boosted its stake in IDEXX Laboratories by 17,238.5% during the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock worth $1,139,000 after acquiring an additional 2,241 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Up 2.7 %

Shares of NASDAQ:IDXX opened at $428.59 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a market cap of $35.10 billion, a P/E ratio of 41.33, a PEG ratio of 3.64 and a beta of 1.36. The stock’s fifty day moving average price is $459.21 and its 200-day moving average price is $480.12.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. During the same quarter in the prior year, the business earned $2.53 EPS. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of analyst reports. JPMorgan Chase & Co. decreased their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Barclays reduced their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Finally, Piper Sandler restated a “neutral” rating and set a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $552.38.

Get Our Latest Research Report on IDXX

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

See Also

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).